ScholarWorks@Korea University College of Medicine: Song, Joon Young

Detailed Information

Song, Joon Young (송준영)

Guro Hospital (Department of Infectious Diseases, Guro Hospital)

Research Area

Tel +82226263051
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

COVID19:33||SARSCoV2:27||Influenza:22||Vaccination:16||Streptococcus pneumoniae:12||HIV:11||Safety:10||vaccine:10||Immunogenicity:10||Korea:9||Pneumonia:8||Epidemiology:8||influenza:8||Vaccine:8||Adult:7||Streptococcus agalactiae:6||immunogenicity:6||Vaccines:6||Pneumococcal conjugate vaccine:6||influenza vaccine:6||Effectiveness:5||Mortality:5||Pneumococcal infections:5||epidemiology:4||Diagnosis:4||Human immunodeficiency virus:4||Acinetobacter baumannii:4||Risk factors:4||pneumonia:4||Influenza vaccine:4||Immunization:4||Communicable diseases:4||HIV/AIDS:4||Guideline:4||elderly:3||Pregnancy:3||Risk factor:3||influenza A virus:3||Surveillance:3||reactogenicity:3||Hospitalization:3||Influenza vaccines:3||Incidence:3||influenza vaccines:3||cellular immunity:3||Hantaan virus:3||Treatment:3||Hantavirus:3||MF59:3||Republic of Korea:3||herpes zoster:3||Disease burden:3||AIDSrelated opportunistic infections:3||2009 H1N1:3||Influenza A virus:3||humoral immunity:3||Autoimmune inflammatory rheumatic disease:2||effectiveness:2||HI antibody:2||surveillance:2||Influenza B virus:2||Disease outbreaks:2||Influenza Vaccines:2||Seroprevalence:2||vaccination:2||Disease transmission:2||Serotype:2||Serotyping:2||variants of concern:2||Childbearing age:2||Children:2||Pandemic:2||인플루엔자:2||지침:2||Pandemics:2||Drug resistance:2||hospitalization:2||human:2||Invasive pneumococcal disease:2||human immunodeficiency virus:2||immunoassay:2||Perception:2||COVID19 vaccination:2||incidence:2||Korea HIV:2||influenzalike illness:2||T cell immune response:2||Communityacquired pneumonia:2||Antiretroviral therapy highly active:2||Antiretroviral agents:2||Coronavirus:2||Candida:2||Pneumococcal Infections:2||Emulsion adjuvant:2||Antiviral:2||Herpes zoster:2||Cardiovascular diseases:2||Vaccine Efficacy:2||mortality:2||Pneumococcal pneumonia:2||Casecontrol study:2||Pneumococcal vaccines:2||Pneumococcus:2||Voriconazole:2||Human:2||opsonophagocytic killing assay:2||Measles:2||DNA vaccine:2||Fever of unknown origin:2||Middle East respiratory syndrome:2||antiviral agents:2||Cellular immunity:2||Cohort studies:2||Cohort study:2||Immunity:2||procalcitonin:2||prognosis:2||Adverse Event:2||breakthrough infection:2||Recombinant protein vaccine:2||H1N1:2||capsular polysaccharide:2||Inactivated:2||safety:2||Renal insufficiency:2||Respiratory syncytial virus:2||Nanoparticle vaccine:2||Respiratory virus:2||costeffectiveness:2||cytokine:2||Antiretroviral therapy:2||Infection control:2||Hospital planning:1||Hospitalacquired MRSA:1||Humoral Immunity:1||Humoral immunity:1||Hydroxychloroquine:1||Hypersensitivity pneumonitis:1||IFNgamma:1||IP10:1||IS1216:1||Imnnumocompromised host:1||Implantable:1||In vivo:1||Inactivated quadrivalent influenza vaccine:1||Infected aortic aneurysm:1||Infection:1||Infectious arthritis:1||Infectious diseases consultation:1||Influenza A(H7N9) virus:1||Influenza B:1||Influenza C virus:1||Influenza vaccination:1||Influenza, human:1||Influenzalike Illness:1||Intensive Care Unit:1||Intradermal injection:1||Intradermal injections:1||Intramuscular injection:1||Invasive aspergillosis:1||JarischHerxheimer reaction:1||Kikuchi disease:1||Lactococcus lactis:1||Lgt:1||Liver Abscess:1||Liver Cirrhosis:1||Lopinavir:1||Loss to follow up:1||Low birth weight:1||Low level fluoroquinolone resistance:1||Lupus nephritis:1||MCP1:1||MERS:1||MF59 adjuvant:1||MF59 oil emulsion:1||MHC class I multimer:1||Macrolides:1||Maternal Welfare:1||Metapneumovirus:1||Metformin:1||Middle East respiratory syndrome coronavirus:1||Middle east respiratory syndrome coronavirus:1||Miliary tuberculosis:1||Monitoring:1||Montreal Cognitive Assessment:1||Mucosal immunity:1||Multilocus Sequence Typing:1||Multilocus sequence typing:1||Mycoplasma pneumoniae:1||Myocarditis:1||NK cells:1||NKG2A:1||Nalidixic acid:1||Narcolepsy:1||National Cohort:1||Neuropsychological test:1||Nocardiosis:1||NonNIP:1||Nontyphoidal Salmonella:1||Novel coronavirus disease 2019 (COVID19):1||ORF3a:1||Obesity:1||Omicron:1||Omicron BA.1:1||Omicron BA.2:1||Opsonophagocytic killing assay:1||Osteomyelitis:1||Outbreak:1||Outbreaks:1||PCR:1||PCV13:1||PFGE:1||PFGE (electrophoresis, gel, pulsedfield):1||PPSV23:1||Pacemaker:1||Pathology:1||Patienttoprofessional:1||Peramivir:1||Pericarditis:1||Periodic fever:1||Persistence of immune response:1||Personal protective equipment:1||Pertussis:1||Phlebovirus:1||Phylogenetic analysis:1||Physician:1||Pneumococcal Conjugate Vaccine:1||Pneumococcal Pneumonia:1||Pneumococcal Polysaccharide Vaccine:1||Pneumococcal Vaccines:1||Pneumococcal disease:1||Pneumococcal infection:1||Pneumococcal polysaccharide vaccine:1||Pneumococcal vaccine:1||Pneumocystis jiroveci:1||Pointofcare systems:1||Policy:1||Polymerase chain reaction:1||Polysaccharides:1||Prednisolone:1||Pregnant Women:1||Preterm birth:1||Prevalence:1||Prognosis:1||Prosthesisrelated infections:1||Psoas muscle:1||Public Health Response:1||Pulmonary:1||QIV:1||Quality control:1||Quarantine:1||RMET:1||Racemose:1||Rectal Surveillance:1||Rectal colonization:1||Recurrence:1||Respiratory tract pathogens:1||Rifampicin:1||Risk Factor:1||Ritonavir:1||SARSCoV2 Omicron Variant:1||SARSCoV2 infection:1||ST19:1||Saliva:1||Salmonella typhimurium:1||Screening method:1||Septic Shock:1||Septic arthritis:1||Sequential vaccination:1||Seroepidemiology:1||Serosurveillance:1||Severe Sepsis:1||Sexually transmitted diseases:1||Skull base:1||Social Distancing:1||Social distancing:1||South Korea:1||Spondylodiscitis:1||Stomach neoplasms:1||Streptococcus:1||Streptococcus pneumonia:1||Subarachnoid:1||Suction mediated in vivo transfection:1||Surgical departments:1||Survey:1||Survival rates:1||Symptom:1||Syphilis:1||TIV:1||Tdap:1||Tetanus:1||Thyroiditis:1||Tissue biopsy:1||Toxocara canis:1||Tuberculoma:1||Tuberculosis:1||Tuberculous lymphadenitis:1||Urinary tract infection:1||VPD:1||Vaccine Effectiveness:1||Vaccine effectiveness:1||Vaccinepreventable diseases:1||Vancomycin resistance:1||VancomycinResistant Enterococci:1||Vancomycinresistant enterococci (VRE):1||Vancomycinresistant enterococcus:1||Varicella zoster virus:1||Viral Load:1||Virus shedding:1||Water wells:1||acquired immunodeficiency syndrome:1||acute fibrinous and organizing pneumonia:1||adult:1||adult vaccination:1||adult vaccines:1||ancestral:1||antibody:1||antimicrobial interactions:1||antiviral therapy:1||anxiety symptom:1||aspergillosis:1||atherosclerosis:1||attenuation:1||averted outcomes:1||awareness:1||bivalent vaccine:1||booster:1||booster vaccination, influenza:1||burden of disease:1||cancer:1||cardiopulmonary disease:1||cell culture techniques:1||cervical lymphadenitis:1||cervical lymphadenopathy:1||ciclesonide:1||clinical trial:1||communityacquired pneumonia:1||coreneedle gun biopsy:1||corticosteroid:1||crossneutralization:1||dengue hemorrhagic fever:1||depressive symptom:1||diagnosis:1||disease burden:1||drug resistance:1||emerging:1||enhanced respiratory disease:1||enzymelinked immunosorbent assay:1||eosinophilia:1||epidemics:1||functional markers:1||gamma irradiation inactivation:1||geometric mean titer:1||geometric mean titer ratio:1||gray scale sonography:1||group B Streptococcus:1||group B streptococcus:1||gut microbiota:1||health behavior:1||health education:1||health service:1||health surveys:1||healthcare cost:1||healthcare worker:1||hemodialysis patients influenza vaccination:1||hemophagocyticlymphohistiocytosis:1||hemorrhagic fever with renal syndrome:1||high dose quadrivalent influenza vaccine:1||hospital mortality:1||hospitalbased influenza morbidity and mortality (HIMM):1||host immune response:1||human Influenza:1||immunerelated adverse event:1||immunity:1||inactivated:1||inactivated vaccine:1||influenza B virus:1||influenza, vaccination:1||inhalation:1||intradermal:1||intradermal vaccine:1||killing kinetics:1||latch:1||lipoprotein:1||live attenuated vaccine:1||live vaccine:1||liver cirrhosis:1||long COVID19:1||longevity:1||lot consistency:1||mRNA Vaccine:1||mRNA vaccine:1||mRNA vaccines:1||mRNA1273 vaccine:1||maternal immunization:1||matrix metalloproteinase13:1||memory cell:1||metaanalysis:1||mucosal immunity:1||multidrug resistance gene:1||mutation genetics:1||neuraminidase:1||neuropsychological tests:1||neutralizing:1||neutralizing activity:1||neutralizing antibody:1||older Population:1||older adults:1||oseltamivir:1||p38 mitogenactivated protein kinase:1||pandemic:1||pathology:1||pembrolizumab:1||pep27 mutant:1||pneumococcal vaccination:1||pneumococcal vaccine:1||pneumonitis:1||postacute sequelae:1||postfusion F:1||power Doppler sonography:1||prefusion F:1||prevalence:1||programmed cell death 1 inhibitor:1||public health:1||quadrivalent influenza vaccine:1||quadrivalent vaccine:1||radiation:1||recovered patient:1||renal dialysis:1||respiratory disorder:1||respiratory syncytial virus:1||rich repeat:1||risk factors:1||salmonella enteritidis:1||salmonella infections:1||salmonella typhimunum:1||screening tool:1||sensitivity:1||sequential vaccination:1||serine:1||seroprevalence:1||severe acute respiratory syndrome coronavirus 2:1||severe dengue:1||social distancing:1||sonography:1||specificity:1||srr1/2:1||standardized mortality ratio:1||strategy:1||substitution:1||subway:1||survival:1||synergy:1||systemic review:1||taxonomic markers:1||tickborne encephalitis:1||tickborne encephalitis virus:1||timekill assay:1||toxocariasis:1||trivalent influenza vaccine:1||ulcerative colitis:1||vaccine preventable diseases:1||vaccine effectiveness:1||vaccines:1||validation:1||varicella:1||varicella zoster virus:1||victoria lineage:1||yamagata lineage:1||감염관리:1||군인:1||스테로이드:1||아데노바이러스:1||중증:1||체외막 산소공급:1||치료:1||폐렴:1||.:1||항바이러스제:1||23valent pneumococcal vaccine:1||A. baumannii:1||AIDS:1||AIDS Cohort Study:1||AIDS cohort:1||Acinetobacter infections:1||Acquired immunodeficiency syndrome:1||Acute respiratory infection:1||Adenovirus Vector:1||Adherence:1||Adjuvants:1||Adolescents:1||Advanced cirrhosis:1||Adverse Events:1||Aged:1||Ageusia:1||Albendazole:1||Anosmia:1||Antibacterial agents:1||Antibacterial agents:1||Antibiotic susceptibility:1||Antibodies:1||Antigenic determinants:1||Antimicrobial treatment:1||Antiretroviral treatment:1||Antiviral agents:1||Anxiety:1||Arthritis:1||Artificial:1||Asia Pacific:1||Asymptomatic infection:1||Awareness:1||Bacteremia:1||Bacterial:1||Bacterial Capsules:1||Bacteriuria:1||Biofilm:1||Broadspectrum protection:1||Bunyaviridae infections:1||Creactive protein:1||CD8+ T cell:1||COVID19 vaccines:1||Campylobacter:1||Capsular serotype:1||Cefditoren:1||Cell culture techniques:1||Cellular Immunity:1||Cervical lymphadenitis:1||Chemoprophylaxis:1||Chemotherapy:1||Child:1||Chlorhexidine:1||Chronic Disease:1||Chronic cardiovascular disease:1||Chronic disease:1||Chronic hepatitis B:1||Chronic respiratory disease:1||Clinical Trial:1||Clinical characteristics:1||Closecontact transmission:1||Clostridium septicum:1||CoInfection:1||Cohort Study:1||Coinfection:1||Colistin:1||Colon cancer:1||Colorectal neoplasms:1||Combination drug therapy:1||Community treatment center:1||CommunityAcquired Pneumonia:1||Communityacquired MRSA:1||Complication:1||Control:1||Coronavirus Disease 2019:1||Cost of illness:1||Costeffectiveness:1||Cysticercosis:1||D614G:1||Data accuracy:1||Data adjustment:1||Data quality:1||Defibrillators:1||Depression:1||Diabetic foot:1||Digital device:1||Digital health care monitoring system:1||Diphtheria:1||Disinfection:1||Distribution:1||Domestic animals:1||EMA:1||East Asia:1||Echinocandins:1||Economic burden:1||Economic evaluation:1||Elderly:1||Empyema:1||Endocarditis:1||Enterococcus:1||Etiology:1||European Medicines Agency:1||Exercise:1||Frail elderly:1||GBS:1||GMT:1||GMTR:1||Gender:1||Guidelines:1||H1N1 influenza A:1||H5N1:1||H7N9 Virus:1||HBsAg:1||HIV Infection:1||HIV infection:1||HIVassociated neurocognitive disorder:1||HIVassociated neurocognitive disorder (HAND):1||HIVinfected patients:1||Hantaan virus vaccines:1||Health personnel:1||Health survey:1||Health surveys:1||Healthcare Worker:1||Healthy person:1||Hemorrhagic fever with renal syndrome:1||Hepatitis A:1||Hepatitis A virus:1||Hepatitis B Virus:1||Hepatitis B virus:1||Hepatitis C virus:1||Histiocytic necrotizing lymphadenitis:1||History:1||

STATISTICS: Total View :12,735,584; Today View :19,605

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE